Laboratory Medicine ›› 2023, Vol. 38 ›› Issue (5): 497-501.DOI: 10.3969/j.issn.1673-8640.2023.05.017
Previous Articles Next Articles
Received:
2022-01-20
Revised:
2022-11-25
Online:
2023-05-30
Published:
2023-08-07
CLC Number:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2023.05.017
项目 | SCr/(μmol/L) | 绝对偏差/(μmol/L) | 相对偏差/% | |
---|---|---|---|---|
cobas c702 | AU680 | |||
5月9日 | ||||
初检 | 99.1±1.0 | 375.4±3.1 | 276.3 | 278.79 |
复检 | 101.4±0.9 | 367.3±2.8 | 265.9 | 263.37 |
5月16日 | ||||
初检 | 99.2±0.4 | 387.2±4.1 | 288.0 | 290.91 |
复检 | 99.4±1.1 | 382.7±3.7 | 283.3 | 285.86 |
项目 | SCr/(μmol/L) | 绝对偏差/(μmol/L) | 相对偏差/% | |
---|---|---|---|---|
cobas c702 | AU680 | |||
5月9日 | ||||
初检 | 99.1±1.0 | 375.4±3.1 | 276.3 | 278.79 |
复检 | 101.4±0.9 | 367.3±2.8 | 265.9 | 263.37 |
5月16日 | ||||
初检 | 99.2±0.4 | 387.2±4.1 | 288.0 | 290.91 |
复检 | 99.4±1.1 | 382.7±3.7 | 283.3 | 285.86 |
样本 | SCr/(μmol/L) | 绝对偏差/(μmol/L) | 相对偏差/% | |
---|---|---|---|---|
cobas c702 | AU680 | |||
H2O | 0.0±0.0 | 0.9±0.0 | 0.9 | — |
L1 | 36.8±0.3 | 38.1±0.4 | 1.3 | 3.53 |
L2 | 42.1±0.2 | 43.0±0.3 | 0.9 | 2.14 |
N1 | 75.6±0.8 | 77.2±1.2 | 1.6 | 2.12 |
N2 | 88.4±1.1 | 89.2±1.5 | 0.8 | 0.90 |
H1 | 518.6±3.5 | 553.5±4.8 | 34.9 | 6.73 |
H2 | 636.5±5.2 | 662.4±5.5 | 25.9 | 4.07 |
P09 | 99.2±0.6 | 378.9±2.3 | 279.7 | 281.96 |
P16 | 100.1±1.2 | 382.4±2.8 | 282.3 | 282.02 |
样本 | SCr/(μmol/L) | 绝对偏差/(μmol/L) | 相对偏差/% | |
---|---|---|---|---|
cobas c702 | AU680 | |||
H2O | 0.0±0.0 | 0.9±0.0 | 0.9 | — |
L1 | 36.8±0.3 | 38.1±0.4 | 1.3 | 3.53 |
L2 | 42.1±0.2 | 43.0±0.3 | 0.9 | 2.14 |
N1 | 75.6±0.8 | 77.2±1.2 | 1.6 | 2.12 |
N2 | 88.4±1.1 | 89.2±1.5 | 0.8 | 0.90 |
H1 | 518.6±3.5 | 553.5±4.8 | 34.9 | 6.73 |
H2 | 636.5±5.2 | 662.4±5.5 | 25.9 | 4.07 |
P09 | 99.2±0.6 | 378.9±2.3 | 279.7 | 281.96 |
P16 | 100.1±1.2 | 382.4±2.8 | 282.3 | 282.02 |
稀释比例(血清∶H2O) | SCr/(μmol/L) | 绝对偏差/(μmol/L) | 相对偏差/% | |
---|---|---|---|---|
Cobas c702 | AU680 | |||
P09 | ||||
1∶0 | 99.2±0.9 | 378.9±3.8 | 279.7 | 281.96 |
1∶1 | 52.3±0.4 | 109.6±1.5 | 57.3 | 109.62 |
1∶2 | 34.1±0.2 | 35.0±0.6 | 1.1 | 2.94 |
1∶3 | 25.0±0.4 | 26.2±0.7 | 1.2 | 4.00 |
P16 | ||||
1∶0 | 100.1±0.8 | 382.4±3.6 | 282.3 | 282.02 |
1∶1 | 55.1±0.7 | 111.6±1.7 | 56.5 | 101.82 |
1∶2 | 38.0±0.4 | 39.0±0.7 | 1.0 | 2.63 |
1∶3 | 24.1±0.5 | 25.0±1.0 | 0.9 | 4.17 |
稀释比例(血清∶H2O) | SCr/(μmol/L) | 绝对偏差/(μmol/L) | 相对偏差/% | |
---|---|---|---|---|
Cobas c702 | AU680 | |||
P09 | ||||
1∶0 | 99.2±0.9 | 378.9±3.8 | 279.7 | 281.96 |
1∶1 | 52.3±0.4 | 109.6±1.5 | 57.3 | 109.62 |
1∶2 | 34.1±0.2 | 35.0±0.6 | 1.1 | 2.94 |
1∶3 | 25.0±0.4 | 26.2±0.7 | 1.2 | 4.00 |
P16 | ||||
1∶0 | 100.1±0.8 | 382.4±3.6 | 282.3 | 282.02 |
1∶1 | 55.1±0.7 | 111.6±1.7 | 56.5 | 101.82 |
1∶2 | 38.0±0.4 | 39.0±0.7 | 1.0 | 2.63 |
1∶3 | 24.1±0.5 | 25.0±1.0 | 0.9 | 4.17 |
仪器 | 检测方法 | 反应原理 | R1试剂 | R2试剂 |
---|---|---|---|---|
cobasc 702 | 酶比色法 | 肌酐+H2O→肌酸 肌酸+H2O→肌氨酸+尿素 肌氨酸+O2+H2→甘氨酸+ 甲醛+H2O2 H2O2+4-AAP①+HTIB→醌亚 胺+H2O+HI 2,4,6-三碘-3- 羟基苯甲酸 | 肌酸酶(微生物)≥332 μkat/L; 肌氨酸氧化酶(微生物)≥132 μkat/L; 抗维生素C氧化酶(微生物)≥33 μkat/L; HTIB 1.2 g/L | 抗维生素C氧化酶(微生物)≥498 μkat/L; 辣根过氧化物酶≥ 16.6 μkat/L; 4-AAP 0.5 g/L; 六氰合铁化钾(Ⅱ) 60 mg/L |
AU680 | 肌氨酸氧化酶法 | 肌酐+H2O→肌酸 肌酸+H2O→肌氨酸+尿素 肌氨酸+O2→甘氨酸+甲醛+H2O2 2H2O2+4-AAP+TOOS→醌亚胺 色素 | TOOS 0.2 g/L; 肌氨酸氧化酶≥10k U/L; 肌酸酶≥40 kU/L; 抗维生素C氧化酶 1 kU/L | 肌酐酶≥350 kU/L; 过氧化物酶 2 kU/L; 4-AAP 0.2 g/L |
仪器 | 检测方法 | 反应原理 | R1试剂 | R2试剂 |
---|---|---|---|---|
cobasc 702 | 酶比色法 | 肌酐+H2O→肌酸 肌酸+H2O→肌氨酸+尿素 肌氨酸+O2+H2→甘氨酸+ 甲醛+H2O2 H2O2+4-AAP①+HTIB→醌亚 胺+H2O+HI 2,4,6-三碘-3- 羟基苯甲酸 | 肌酸酶(微生物)≥332 μkat/L; 肌氨酸氧化酶(微生物)≥132 μkat/L; 抗维生素C氧化酶(微生物)≥33 μkat/L; HTIB 1.2 g/L | 抗维生素C氧化酶(微生物)≥498 μkat/L; 辣根过氧化物酶≥ 16.6 μkat/L; 4-AAP 0.5 g/L; 六氰合铁化钾(Ⅱ) 60 mg/L |
AU680 | 肌氨酸氧化酶法 | 肌酐+H2O→肌酸 肌酸+H2O→肌氨酸+尿素 肌氨酸+O2→甘氨酸+甲醛+H2O2 2H2O2+4-AAP+TOOS→醌亚胺 色素 | TOOS 0.2 g/L; 肌氨酸氧化酶≥10k U/L; 肌酸酶≥40 kU/L; 抗维生素C氧化酶 1 kU/L | 肌酐酶≥350 kU/L; 过氧化物酶 2 kU/L; 4-AAP 0.2 g/L |
样本 | 第1次检测 | 第2次检测 | 第3次检测 | $\bar{x}±s$ |
---|---|---|---|---|
H2O | 0.1 | 0.1 | 0.0 | 0.1±0.1 |
L | 17.9 | 16.3 | 17.4 | 17.2±0.7 |
N | 13.8 | 15.3 | 13.3 | 14.1±0.9 |
H | 20.4 | 19.9 | 20.7 | 20.3±0.3 |
P09 | 57.3 | 59.2 | 57.4 | 58.0±0.9 |
P16 | 60.2 | 60.7 | 62.5 | 61.1±1.0 |
样本 | 第1次检测 | 第2次检测 | 第3次检测 | $\bar{x}±s$ |
---|---|---|---|---|
H2O | 0.1 | 0.1 | 0.0 | 0.1±0.1 |
L | 17.9 | 16.3 | 17.4 | 17.2±0.7 |
N | 13.8 | 15.3 | 13.3 | 14.1±0.9 |
H | 20.4 | 19.9 | 20.7 | 20.3±0.3 |
P09 | 57.3 | 59.2 | 57.4 | 58.0±0.9 |
P16 | 60.2 | 60.7 | 62.5 | 61.1±1.0 |
肌酸(nmol/mL) | SCr(μmol/L) | ||||
---|---|---|---|---|---|
cobas c702 | AU680 | ||||
加入前 | 加入后 | 加入前 | 加入后 | ||
20.0 | 58.9 | 59.3 | 57.4 | 59.2 | |
40.0 | 59.6 | 59.7 | 61.3 | 68.9 | |
60.0 | 60.1 | 59.4 | 59.6 | 212.4 | |
80.0 | 59.1 | 77.1 | 58.5 | 317.9 | |
100.0 | 60. 2 | 161.1 | 59.4 | 517.9 |
肌酸(nmol/mL) | SCr(μmol/L) | ||||
---|---|---|---|---|---|
cobas c702 | AU680 | ||||
加入前 | 加入后 | 加入前 | 加入后 | ||
20.0 | 58.9 | 59.3 | 57.4 | 59.2 | |
40.0 | 59.6 | 59.7 | 61.3 | 68.9 | |
60.0 | 60.1 | 59.4 | 59.6 | 212.4 | |
80.0 | 59.1 | 77.1 | 58.5 | 317.9 | |
100.0 | 60. 2 | 161.1 | 59.4 | 517.9 |
[1] | 徐国宾, 李志艳. 应重视实验室检查在慢性肾病早期诊断中的应用[J]. 中华检验医学杂志, 2006, 29(11):961-965. |
[2] | 周碧燕, 李友邕, 覃政, 等. 血清肌酐常规测定方法和临床应用的研究进展[J]. 化学试剂, 2011, 33(8):718-722. |
[3] | 陈剑, 罗曼玲, 张大莲, 等. IgM大分子蛋白致酶法检测血清肌酐呈假阳性增高一例[J]. 临床医学, 2019, 39(3):125-126. |
[4] | 中国合格评定国家认可委员会. CNAS-GL037:2019 临床化学定量检验程序性能验证指南[S]. 北京: 中国合格评定国家认可委员会, 2019. |
[5] | 尚红, 王毓三, 申子瑜. 全国临床检验操作规程[M]. 4版. 北京: 人民卫生出版社, 2015. |
[6] |
RAKESH KUMAR R K, SHAIKH M O, CHUANG C H. A review of recent advances in non-enzymatic electrochemical creatinine biosensing[J]. Anal Chim Acta, 2021, 1183:338748.
DOI URL |
[7] | 王正印, 尹元, 王伟灵. 肌酐检测方法及常见药物对肌酐检测干扰的研究进展[J]. 检验医学, 2018, 33(4):370-373. |
[8] | 李伦, 王兵, 刘匀慧. 肌酐酶法和苦味酸法检查血清及尿肌酐值的结果分析[J]. 深圳中西医结合杂志, 2021, 31(12):96-98. |
[9] | 石文, 黄婕如, 刘冬冬, 等. 应用CLSI EP7-A3评价肌酐测定的干扰因素[J]. 中华检验医学杂志, 2020, 43(3):307-311. |
[10] | 程武, 连国军, 谢径峰. 血清肌酐可见光匀相速率法检测技术的建立[J]. 福建医药杂志, 2010, 32(5):90-92. |
[11] | 程武. 血清肌酐匀相法检测新技术的研究[D]. 福州: 福建医科大学, 2009. |
[12] | 程武, 连国军. 血清肌酐测定方法学进展及其评价[J]. 中国保健, 2009, 17(15):562-565. |
[13] | 钱芳, 陈玉. 羟苯磺酸钙药物浓度对肌氨酸氧化酶法检测肌酐的干扰试验分析[J]. 检验医学与临床, 2022, 19(6):843-844. |
[1] | FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114. |
[2] | SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120. |
[3] | LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129. |
[4] | YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140. |
[5] | XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146. |
[6] | CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152. |
[7] | . [J]. Laboratory Medicine, 2023, 38(12): 1153-1156. |
[8] | . [J]. Laboratory Medicine, 2023, 38(12): 1157-1159. |
[9] | WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(12): 1160-1166. |
[10] | YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172. |
[11] | DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176. |
[12] | GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182. |
[13] | . [J]. Laboratory Medicine, 2023, 38(12): 1183-1185. |
[14] | . [J]. Laboratory Medicine, 2023, 38(12): 1186-1190. |
[15] | . [J]. Laboratory Medicine, 2023, 38(12): 1191-1194. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||